National Cancer Intelligence Network
Cancer statistics: availability and location

July 2015 update
About Public Health England

Public Health England exists to protect and improve the nation’s health and wellbeing, and reduce health inequalities. It does this through world-class science, knowledge and intelligence, advocacy, partnerships and the delivery of specialist public health services. PHE is an operationally autonomous executive agency of the Department of Health.

Public Health England
Wellington House
133-155 Waterloo Road
London SE1 8UG
Tel: 020 7654 8000
www.gov.uk/phe
Twitter: @PHE_uk
Facebook: www.facebook.com/PublicHealthEngland

Prepared by: members of the central analytical team at the National Cancer Intelligence Network (NCIN).

© Crown copyright 2014
This publication is licensed under the terms of the Open Government Licence v3.0 except where otherwise stated. To view this licence, visit nationalarchives.gov.uk/doc/open-government-licence/version/3 or write to the Information Policy Team, The National Archives, Kew, London TW9 4DU, or email: psi@nationalarchives.gsi.gov.uk

Where we have identified any third party copyright information you will need to obtain permission from the copyright holders concerned.

Any enquiries regarding this publication should be sent to us at publications@phe.gov.uk

Published July 2015
PHE publications gateway number: 2015207

This document is available in other formats on request. Please call 020 7654 8158 or email ncinanalysts@phe.gov.uk
The intelligence networks

Public Health England operates a number of intelligence networks, which work with partners to develop world-class population health intelligence to help improve local, national and international public health systems.

National Cancer Intelligence Network

The National Cancer Intelligence Network (NCIN) is a UK-wide initiative, working to drive improvements in cancer awareness, prevention, diagnosis and clinical outcomes by improving and using the information collected about cancer patients for analysis, publication and research.

National Cardiovascular Intelligence Network

The National Cardiovascular Intelligence Network (NCVIN) analyses information and data and turns it into meaningful timely health intelligence for commissioners, policy makers, clinicians and health professionals to improve services and outcomes.

National Child and Maternal Health Intelligence Network

The National Child and Maternal Health Intelligence Network provides information and intelligence to improve decision-making for high-quality, cost-effective services. Its work supports policy makers, commissioners, managers, regulators, and other health stakeholders working on children’s, young people’s and maternal health.

National Mental Health Intelligence Network

The National Mental Health Intelligence Network (NMHIN) is a single shared network in partnership with key stakeholder organisations. The network will seek to put information and intelligence into the hands of decision makers to improve mental health and wellbeing.

National End of Life Care Intelligence Network

The National End of Life Care Intelligence Network (NEoLCIN) aims to improve the collection and analysis of information related to the quality, volume and costs of care provided by the NHS, social services and the third sector to adults approaching the end of life. This intelligence will help drive improvements in the quality and productivity of services.
# Contents

<table>
<thead>
<tr>
<th>Topic</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>About Public Health England</td>
<td>2</td>
</tr>
<tr>
<td>The intelligence networks</td>
<td>3</td>
</tr>
<tr>
<td>Executive summary</td>
<td>5</td>
</tr>
<tr>
<td>Measuring improvements in cancer outcomes</td>
<td>6</td>
</tr>
<tr>
<td>Cancer incidence</td>
<td>6</td>
</tr>
<tr>
<td>Cancer mortality</td>
<td>10</td>
</tr>
<tr>
<td>Cancer survival</td>
<td>13</td>
</tr>
<tr>
<td>Improving outcomes for cancer patients: prevention and early diagnosis</td>
<td>16</td>
</tr>
<tr>
<td>Cancer awareness</td>
<td>16</td>
</tr>
<tr>
<td>Participation in screening</td>
<td>18</td>
</tr>
<tr>
<td>Routes to diagnosis</td>
<td>22</td>
</tr>
<tr>
<td>Improving outcomes for cancer patients: quality of life and patient experience</td>
<td>24</td>
</tr>
<tr>
<td>Cancer prevalence</td>
<td>24</td>
</tr>
<tr>
<td>Patient experience</td>
<td>26</td>
</tr>
<tr>
<td>Quality of life</td>
<td>27</td>
</tr>
<tr>
<td>Quality of care</td>
<td>28</td>
</tr>
<tr>
<td>Improving outcomes for cancer patients: better treatment</td>
<td>29</td>
</tr>
<tr>
<td>Treatment and quality of care</td>
<td>29</td>
</tr>
<tr>
<td>Treatment outcomes data</td>
<td>32</td>
</tr>
<tr>
<td>Improving outcomes for cancer patients: reducing inequalities</td>
<td>33</td>
</tr>
<tr>
<td>Glossary of terms</td>
<td>35</td>
</tr>
</tbody>
</table>
Executive summary

This document aims to provide an overview about cancer statistics, including information on the latest statistics publicly available and where to find them.

This is intended to be a useful reference guide for infrequent users of cancer statistics or for audiences that may not be familiar with this information. This document is structured using key chapters in the ‘Improving Outcomes: a Strategy for Cancer’ report.
Measuring improvements in cancer outcomes

Cancer incidence

What is it?

The number of new cases of cancer diagnosed for a given period, usually a year. The statistics are provided as the total number of cases or as rates (number of cases per 100,000 population).

Incidence rates can be ‘crude’ or age-standardised. The crude rate is calculated by dividing the number of patients who live in a given area by the population of that area, however, the age-standardised rate (ASR) is more commonly used because the incidence of cancer rises sharply with age. The ASR calculation takes into account the variation in the age structures of populations to allow comparisons between different areas to be made. Cancer is much more common in the elderly, so a more elderly population will in general have a higher crude rate. Therefore age-standardised rates are the figures that should be used when making comparisons between different areas or different time periods, if one wishes to account for differences in the age distribution. ASRs are most commonly standardised using the European Standard Population or World Standard Population statistics.

What is the latest data available?

- UK and regional data: 2013
- England: 2013
- European and international comparators: 2012
- Projections: predictions for 2020 in England; predictions up to 2035 for the UK

Useful data sources:

UK and regional statistics:

- the National Cancer Registration Service’s (NCRS) cascade system is an online analytical tool providing incidence, mortality and survival data for the cancer analytical community for which login access is needed: nww.cancerstats.encore.nhs.uk/users/sign_in. Cascade has initial England data for 2013 incidence, 2013 mortality and 2008 to 2012 survival. Celtic country data covers 2010 incidence, with updated mortality and survival being added in the future
Cancer Research UK (CRUK) provides detailed information about cancer incidence up to 2011. This data is available on the CRUK website at: www.cancerresearchuk.org/cancer-info/cancerstats/incidence/

Macmillan cancer support also provide information at CCG level on incidence, mortality, survival and prevalence in the Local Cancer Intelligence tool: lci.cancertoolkit.co.uk/ This data can be downloaded in an .csv format that can be opened in Excel

the Office for National Statistics (ONS) provides cancer incidence, mortality and survival statistics over time, through the release of statistical bulletins. The ONS statistics on incidence up to 2013 are for England and its government office regions. These can be downloaded in an Excel format. This data is available on the ONS website at: www.ons.gov.uk/ons/rel/vsob1/cancer-statistics-registrations--england--series-mb1-/index.html

accompanying this is a statistical bulletin summarizing the 2013 data: www.ons.gov.uk/ons/dcp171778_409714.pdf


a range of statistics are provided by PHE, the Welsh Cancer Intelligence and Surveillance Unit, and the Scottish and Northern Irish Cancer Registries. These include statistics for the different regions in England and for Wales, Scotland and Northern Ireland. Their website addresses are available from the UK and Ireland Association of Cancer Registries (UKIACR) website at: www.ukiacr.org and cancer related indicators are available on www.ukiacr.org/kpis

further links to incidence, mortality and survival data for Scotland, Wales, Northern Ireland and Ireland can be found here: www.ncin.org.uk/cancer_information_tools/eatlas/links_to_useful_data_sources

the Cancer Commissioning Toolkit (CCT) is a web-based database of multiple data sources and also includes incidence, mortality and survival data for commissioners and providers. There are two levels of access – public open access (to comply with the government open data policy) and professional NHS (login required to meet information governance requirements). For more information on the CCT see: www.ncin.org.uk/cancer_information_tools/cct or www.cancertoolkit.co.uk

Gynaecological Cancer Profiles is an online tool providing incidence and mortality

1 PHE incorporates the cancer registration and analytical teams of the former eight cancer registries in England, with the latter team now within the regional knowledge and intelligence teams (KfTs)
rates, survival, and influencing factors, such as deprivation, smoking prevalence and obesity for the main gynaecological cancers. Cervical screening coverage indicators are also available. For further information, see: www.ncin.org.uk/cancer_type_and_topic_specific_work/cancer_type_specific_work/gynaecological_cancer/gynaecological_cancer_hub/profiles

- the Urological Cancer hub is an online tool providing incidence and mortality rates, survival, profiles and influencing factors for the main urological cancers. For further information, see: www.ncin.org.uk/cancer_type_and_topic_specific_work/cancer_type_specific_work/urological_cancer/urological_cancer_hub

- the Skin Cancer hub is an online tool providing incidence and mortality rates, survival, profiles and influencing factors for the main skin cancers. For further information, see: www.swpho.nhs.uk/skincancerhub

- the Head and Neck Cancer hub is an online tool providing incidence and mortality rates, survival, profiles and influencing factors for the main Head & Neck cancers. For further information, see www.ncin.org.uk/cancer_type_and_topic_specific_work/cancer_type_specific_work/head_and_neck_cancers/head_and_neck_cancer_hub

- the NCIN website has a number of publications around incidence that can be found under the publication section of the website: www.ncin.org.uk/publications. More recent publications include:
  o rare and less common cancers
  o older people and cancer
  o major resections by cancer site, in England; 2006 to 2010
  o the third all breast cancer report. Back to basics: Breast cancer incidence and mortality

International comparisons:

- there are a range of sources for European and international cancer incidence statistics. The CANCER Mondial website provides access to various databases containing information on the occurrence of cancer worldwide. It is held and managed by the Section of Cancer Information (CIN) of International Agency for Research on Cancer (IARC). The CANCER Mondial website is: www-dep.iarc.fr

- as an example, GLOBOCAN provides worldwide nation estimates for the incidence of and mortality from major cancer types. The most recent GLOBOCAN estimates are presented for 2012 and can be downloaded as factsheets or tabulations, while charts and predictions can be generated in response to defined search criteria. This data is available on the GLOBOCAN website at: http://globocan.iarc.fr/Default.aspx


- this tool and a range of others can be accessed at the European Cancer Observatory (ECO) site: http://eco.iarc.fr/Default.aspx
Incidence projections:

- projections for CCGs in England are included in Macmillan's Local Cancer Intelligence tool: lci.cancertoolkit.co.uk
- a paper by Macmillan Cancer Support, based on the above data focusing on the cancer burden by 2020 can be found at: www.macmillan.org.uk/Documents/AboutUs/Newsroom/Mortality-trends-2013-executive-summary-FINAL.pdf
- these statistics will be presented on the Cancer Research UK website when available: www.cancerresearchuk.org/cancer-info/cancerstats/incidence/projections
- the Cancer Incidence Projections report gives projections for the number of cancer cases in Scotland up to 2020, with policy and methodology background. It is available on the ISD Scotland website at: www.isdscotland.org/Health-Topics/Cancer/Cancer-Statistics/Cancer-Incidence-Projections-Scotland-to-2020.pdf
- GLOBOCAN provides UK and worldwide incidence (and mortality) predictions for up to 2035 using data held in GLOBOCAN. Predictions can be generated on the future burden of a selected cancer or group of cancers, in a selected group of populations, in a selected year. Available on the GLOBOCAN website at: http://globocan.iarc.fr/Pages/burden_sel.aspx
Cancer mortality

What is it?

Cancer mortality is the number of people who have died from cancer. The statistics show the number and the rate of cancer deaths per year. Cancer mortality is commonly expressed as crude and age-standardised rates in exactly the same way as cancer incidence (see above).

What is the latest data available?

- UK and regional data: 2013
- England: 2013
- European and international comparators: 2012
- Projections: Estimates up to 2035 for the UK

Useful data sources:

UK and regional statistics:

- the NCRS cascade system is an online analytical tool providing incidence, mortality and survival data for the cancer analytical community for which login access is needed: nww.cancerstats.encore.nhs.uk/users/sign_in. Cascade has initial England data for 2013 incidence, 2013 mortality and 2008 to 2012 survival. Celtic country data covers 2010 incidence with updated mortality and survival being added in the future
- CRUK provides detailed information about cancer mortality up to 2012. This data is available on the CRUK website at: www.cancerresearchuk.org/cancer-info/cancerstats/mortality
- Macmillan cancer support also provide information at CCG level on incidence, mortality, survival and prevalence in the Local Cancer Intelligence tool: lci.cancertoolkit.co.uk. This data can be downloaded in a .csv format that can be opened in Excel
- the ONS provides cancer mortality, incidence and survival statistics over time through the release of statistical bulletins. The ONS statistics on mortality up to 2013 are for England and Wales; these can be downloaded in an Excel format. This data is available on the ONS website at: www.ons.gov.uk/ons/rel/vsob1/mortality-statistics--deaths-registered-in-england-and-wales--series-dr-/index.html
- a range of statistics are provided by PHE, the Welsh Cancer Intelligence and Surveillance Unit, and the Scottish and Northern Irish Cancer Registries. These include statistics for the different regions in England and for Northern Ireland, Scotland and Wales. Their website addresses are available from the UK and Ireland Association of Cancer Registries (UKIACR) website at: www.ukiacr.org and cancer related indicators are available on www.ukiacr.org/kpis
• further links to mortality data for Scotland, Wales, Northern Ireland and Ireland can be found here: www.ncin.org.uk/cancer_information_tools/eatlas/links_to_useful_data_sources
• the CCT is a web based database of multiple data sources and also includes incidence, mortality and survival data for commissioners and providers. There are two levels of access – public open access (to comply with the government open data policy) and professional NHS (login required to meet information governance requirements). See www.ncin.org.uk/cancer_information_tools/cct or www.cancertoolkit.co.uk
• the NCIN website has a number of publications around mortality that can be found under the publication section of the website: www.ncin.org.uk/publications, for example a report on rare and less common cancers covering 2010 to 2013
• Gynaecological Cancer Profiles is an online tool providing incidence and mortality rates for the main gynaecological cancers, survival, and influencing factors, such as deprivation, smoking prevalence and obesity. Cervical screening coverage indicators are also available. See: www.ncin.org.uk/cancer_type_and_topic_specific_work/cancer_type_specific_work/gynaecological_cancer/gynaecological_cancer_hub/profiles
• the Urological Cancer hub is an online tool providing incidence and mortality rates, survival, profiles and influencing factors for the main urological cancers. For further information, see: www.ncin.org.uk/cancer_type_and_topic_specific_work/cancer_type_specific_work/urological_cancer/urological_cancer_hub
• the Skin Cancer hub is an online tool providing incidence and mortality rates, survival, profiles and influencing factors for the main skin cancers. For further information, see: www.swpho.nhs.uk/skincancerhub
• the Head and Neck Cancer hub is an online tool providing incidence and mortality rates, survival, profiles and influencing factors for the main Head & Neck cancers. For further information, see: www.ncin.org.uk/cancer_type_and_topic_specific_work/cancer_type_specific_work/head_and_neck_cancers/head_and_neck_cancer_hub

International comparisons:

• there are a range of sources for European and international cancer mortality statistics. The CANCER Mondial website provides access to various databases containing information on the occurrence of cancer worldwide. It is held and managed by the CIN of IARC. The CANCER Mondial website is: www-dep.iarc.fr
• as an example, GLOBOCAN provides worldwide nation estimates for the incidence of and mortality from major cancer types. The most recent GLOBOCAN estimates are presented for 2012 and can be downloaded as factsheets or tabulations, while charts and predictions can be generated in response to defined search criteria. This data is available on the GLOBOCAN website at: http://globocan.iarc.fr/Default.aspx
• EUCAN presents estimates of incidence, mortality and prevalence for 24 major

Mortality projections:

- CRUK provides cancer mortality projections up to 2030 for all cancers combined. This data is available on the CRUK website at: www.cancerresearchuk.org/cancer-info/cancerstats/mortality/mortality-projections
- GLOBOCAN provides UK and worldwide mortality (and incidence) predictions for up to 2035 using data held in GLOBOCAN. Predictions can be generated on the future burden of a selected cancer or group of cancers, in a selected group of populations in a selected year. Available on the GLOBOCAN website at: http://globocan.iarc.fr/Pages/burden_sel.aspx
Cancer survival

What is it?

Survival estimates are the percentage of patients who are still alive a specified time after their diagnosis of cancer. The most common estimates are one-year and five-year survival. There are a number of methods used to calculate cancer survival. The most commonly used method is called relative survival.

Relative survival: provides an estimate of the percentage of patients still alive a specified number of days/months/years from their diagnosis, while taking into account the background mortality in the general population (eg the percentage of patients that would be expected to have died from other causes during that period if they did not have cancer). It is therefore an estimate of the proportion of patients who survive their cancer for the specified time period.

Net survival: accounts for the so-called ‘informative censoring’ bias, ie the fact that some groups of patients are less likely than others to be observed until death, independently of their cancer prognosis. It is the advised method to be used where the cause of death is not known. Net survival probability enables the desired comparability between countries, because it is independent of general population mortality.

What is the latest data available?

- one-year survival: based on patients diagnosed up to 2012
- five-year survival: based on patients diagnosed up to 2008

Useful data sources:

UK and regional statistics:

- CRUK provides detailed information about relative cancer survival on patients diagnosed up to 2010 to 2011. This data is available on the CRUK website at: www.cancerresearchuk.org/cancer-info/cancerstats/survival
- Macmillan cancer support also provide information at CCG level on incidence, mortality, survival and prevalence in the Local Cancer Intelligence tool: lci.cancertoolkit.co.uk
- one year survival is available broken down by TNM stage for England, 2012: www.ncin.org.uk/publications/survival_by_stage
- the ONS provides cancer survival, incidence and mortality statistics over time through the release of statistical bulletins. The ONS survival statistics are produced
in collaboration with the London of School of Hygiene and Tropical Medicine (LSHTM). The latest available ONS statistics provide net survival for patients diagnosed up to 2012 in England; also published are survival statistics for UK, CCGs, cancer network and former PCT areas. This data is available on the ONS website:


- a range of statistics are provided by PHE, the Welsh Cancer Intelligence and Surveillance Unit, and the Scottish and Northern Irish Cancer Registries. These include statistics for the different regions in England and for Northern Ireland, Scotland and Wales. Their website addresses are available from the UKIACR website at: [www.ukiacr.org](http://www.ukiacr.org) and cancer related indicators are available on: [www.ukiacr.org/kpis](http://www.ukiacr.org/kpis)

- the NCRS cascade system is an online analytical tool providing incidence, mortality and survival data for the cancer analytical community for which login access is needed: [www.cancerstats.encore.nhs.uk/users/sign_in](http://www.cancerstats.encore.nhs.uk/users/sign_in). The UKCIS remains temporarily available for reference, but is no longer supported. Cascade has initial England data for 2013 incidence, 2013 mortality and 2008 to 2012 survival. Celtic country data covers 2010 incidence with updated mortality and survival being added in the future

- the CCT is a web based database of multiple data sources and also includes incidence, mortality and survival data for commissioners and providers. There are two levels of access – public open access (to comply with the government open data policy) and professional NHS (login required to meet information governance requirements). See: [www.ncin.org.uk/cancer_information_tools/cct](http://www.ncin.org.uk/cancer_information_tools/cct) or [www.cancertoolkit.co.uk](http://www.cancertoolkit.co.uk)


- Gynaecological Cancer Profiles is an online tool providing incidence and mortality rates for the main gynaecological cancers, survival, and influencing factors, such as deprivation, smoking prevalence and obesity. Cervical screening coverage indicators are also available. See:
• the Urological Cancer hub is an online tool providing incidence and mortality rates, survival, profiles and influencing factors for the main urological cancers. For further information, see www.ncin.org.uk/cancer_type_and_topic_specific_work/cancer_type_specific_work/urological_cancer/urological_cancer_hub

• the Skin Cancer hub is an online tool providing incidence and mortality rates, survival, profiles and influencing factors for the main skin cancers. For further information, see www.swpho.nhs.uk/skincancerhub

• the Head and Neck Cancer hub is an online tool providing incidence and mortality rates, survival, profiles and influencing factors for the main head and neck cancers. For further information, see: www.ncin.org.uk/cancer_type_and_topic_specific_work/cancer_type_specific_work/head_and_neck_cancers/head_and_neck_cancer_hub

• the NCIN website has a number of publications around survival which can be found under the publication section of the website: www.ncin.org.uk/publications. The most viewed publication on survival is ‘Kidney cancer: survival report’.

• more recent publications include:
  o Older people and cancer
  o Cancer survival in England by stage 2012
  o Kidney Cancer: Survival Report

International comparisons:


• there are a range of sources for European and international cancer survival statistics. The CANCER Mondial website provides access to various databases containing information on the occurrence of cancer worldwide. It is held and managed by the CIN of IARC. The CANCER Mondial website is: www-dep.iarc.fr

• as an example, GLOBOCAN provides worldwide nation estimates for the incidence of and mortality from major cancer types. The most recent GLOBOCAN estimates are presented for 2012 and can be downloaded as fact sheets or tabulations, while charts and predictions can be generated in response to defined search criteria. This data is available on the GLOBOCAN website at: globocan.iarc.fr/Default.aspx

• EUROCARE (EUROpean CAncer REgistry-based study on survival and care of cancer patients) is a cancer epidemiology research project on the survival of European cancer patients. A range of data and publications are available on the EUROCARE website at: www.eurocare.it
Improving outcomes for cancer patients: prevention and early diagnosis

Cancer awareness

What is it?

Public awareness of the potential signs and symptoms of cancer, as well as an understanding of when and how to seek help, can play an important part in ensuring that cancer is diagnosed at an early stage.

What is the latest data available?

A range of surveys and research have been carried out looking at cancer awareness over the years. In order to assess levels of public awareness and to track changes over time, and as part of the National Awareness and Early Diagnosis Initiative (NAEDI), Cancer Research UK, University College London, King’s College London and the University of Oxford have developed a Cancer Awareness Measure (CAM) to measure public awareness. The CAM is a validated set of questions designed to reliably assess public awareness of cancer warning signs, anticipated delay and perceived barriers to seeking medical advice. The data come from 2 surveys: 1) an ONS opinions survey that is sampled to be representative of the UK population; and 2) an Ethnibus survey of the main ethnic minority groups in England. Surveys were carried out in 2008, 2010, 2012 and 2014.

Site-specific CAMs have also been completed for breast, colorectal/bowel, cervical, lung and ovarian cancer. These measures were developed with the support of Breakthrough Breast Cancer, Breast Cancer Care, Cancer Research UK, Ovarian Cancer Action, The Eve Appeal, Ovacome, Target Ovarian Cancer and the Department of Health.

Useful data sources:

- further information on how to access detailed statistics on the CAM (including downloads of the data in Excel/database format) is available on the Cancer Research UK website at: www.cancerresearchuk.org/cancer-info/spotcancerearly/naedi/AboutNAEDI/Researchevaluationandmonitoring/naedi_cam
- a CRUK and Tesco report was published in 2012. It details key results from the CAM 2010 survey, the problems of diagnosing cancer early and why we need to solve them. The report ‘Delay Kills’ is available on the CRUK website at: www.cancerresearchuk.org/prod_consump/groups/cr_common/@abt/@gen/docum
• CAM National Baseline Report was published in 2009. The report ‘Public awareness of cancer in Britain’ is available at:

• two papers published in 2009 provide further information about the CAM: K Robb et al. details the process of data collection and analysis in ‘Public awareness of cancer in Britain: a population-based survey of adults’. British Journal of Cancer 2009; 101:S18–S23. See:
  www.nature.com/bjcjournal/v101/n2/full/6605386a.html; and S Stubbings et al. details the ‘Development of a measurement tool to assess public awareness of cancer’. British Journal of Cancer 2009; 101:S13–S17. See:
  www.nature.com/bjcjournal/v101/n2/full/6605385a.html

• the Ovarian CAM has been implemented in the Target Ovarian Cancer pathfinder study. The 2012 Target Ovarian Cancer Pathfinder Study report is available on the Target Ovarian Cancer website at:
  www.targetovariancancer.org.uk/page.asp?section=538&sectionTitle=The+2012+Target+Ovarian+Cancer+Pathfinder+Study

• further site-specific CAMs have been used in national surveys and key results have been published in the following peer-reviewed papers:

International comparisons:

• a comparison between six countries including the UK was published in January 2013 looking at differences in awareness and belief about cancer as part of the International Cancer Benchmarking Partnership: See:
  www.nature.com/bjcjournal/v108/n2/full/bjc2012542a.html
Participation in screening

What is it?

The UK National Screening Committee makes UK-wide policies. It recommends systematic population screening programmes for breast cancer, cervical cancer and bowel cancer. It is up to each part of the UK to determine when, and how, to put those policies into practice. This means that there will be some differences in the screening services available in England, Northern Ireland, Scotland or Wales. A wide range of statistics are published on screening. A key measure used is screening ‘coverage’. Definitions of coverage are given below.

Breast screening:

Purpose: breast screening is intended to detect breast cancer at an early stage, enabling more effective treatment.

Invited population: in the UK, women aged 50 to 70 are routinely invited for breast screening every three years under a national programme. Women over the age of 70 can request screening every three years by making an appointment at their local screening unit, but they do not receive invitations. The NHS Screening Programme in England has, since 2010, been phasing in an extension of the age range of women eligible for breast screening to those aged 47 to 73. In Wales, younger women at increased risk of breast cancer can be referred by the All Wales Cancer Genetics service for screening.

Coverage: defined as the percentage of women resident and eligible for screening at a particular point in time who had a test with a recorded result within the last three years.

Latest review: concluded that the NHS Breast Screening Programmes ‘confers significant benefit and should continue’. Their best estimate is that the Programme prevents 1,300 deaths a year. This report published in October 2012 is available on the Cancer Research website at: www.cancerresearchuk.org/cancer-info/publicpolicy/ourpolicypositions/symptom_Awareness/cancer_screening/breast-screening-review/breast-screening-review?utm_source=Lancet&utm_medium=report&utm_campaign=breast_screen_review

Cervical screening:

Purpose: cervical screening is intended to detect abnormalities within the cervix that could, if untreated, develop into cancer.
Invited population: UK policy on age of commencement and frequency for cervical screening is varied. The cervical screening policy for England and Northern Ireland invites women for screening every three years for those aged 25 to 49 and every five years for those aged 50 to 64. The policy in Wales is to invite women aged 20 to 64 years every three years; and in Scotland to invite women aged 20 to 60 years every three years. From 2013 in Wales, and from 2015 in Scotland, the age of commencement and frequency for cervical screening will align with existing practice in England and Northern Ireland.

Coverage: defined as the percentage of women in a population eligible for screening at a given point in time who were screened adequately within a specified period. As the frequency with which women are invited for screening is dependent on age and country, coverage is calculated differently for different age groups, for example in England and Northern Ireland.

For women aged 25 to 49, coverage is calculated as the number of women in this age group who have had an adequate screening test within the last 3.5 years, as a percentage of the eligible population aged 25 to 49.

For women aged 50 to 64, coverage is calculated as the number of women in this age group who have had an adequate screening test within the last five years, as a percentage of the eligible population aged 50 to 64.

Bowel screening:

Purpose: bowel cancer screening aims to detect bowel cancer at an early stage, when treatment is more likely to be effective or to help prevent cancer from developing in the first place by allowing the treatment of pre-cancerous conditions.

Invited population: all UK programmes invite men and women for bowel screening every two years, however, the age group offered bowel screening varies by country. In Scotland, bowel cancer screening is offered to people aged 50 to 74, in Wales to those aged 60 to 74, and in Northern Ireland to those aged 60 to 71. In England, bowel cancer screening is available to those aged 60 to 69, with this age range currently being extended to 60 to 74. A further 1-off diagnostic test using Flexible Sigmoidoscopy is being piloted in England, aimed at men and women aged 55.

Uptake: Not currently available as national statistics are not yet routinely published (as for the breast and cervical screening programmes), however, statistics can be found in the reports that evaluate the pilots.
What is the latest data available?

Breast screening: 2013 to 2014 (financial year)
Cervical screening: 2012 to 2013 (financial year)
Bowel screening: routine national statistics not yet available

Useful data sources:

- information on the UK Screening Programmes is available on the UK Screening Portal at: www.screening.nhs.uk
- information on the NHS Cancer Screening Programmes in England is available at: www.cancerscreening.nhs.uk
- ‘Over 5% of all cancers are currently diagnosed via screening’ is a statistic quoted from the Department of Health publication ‘Improving outcomes: A Strategy for Cancer’, available at: www.dh.gov.uk/en/Publicationsandstatistics/Publications/PublicationsPolicyAndGuidance/DH_123371. This figure comes from the Routes to Diagnosis analyses [see Routes to Diagnosis section]. A second annual report is available here: www.gov.uk/government/publications/the-national-cancer-strategy-second-annual-report
- screening data for England is available from the CCT, which is a web-based database of multiple data sources and also includes incidence, mortality and survival data for commissioners and providers. There are two levels of access – public open access (to comply with the government open data policy) and professional NHS (login required to meet information governance requirements). See: www.ncin.org.uk/cancer_information_tools/cct or www.cancertoolkit.co.uk

Breast screening statistics for:

- England: Published on the Health and Social Care Information Centre website at: www.hscic.gov.uk/catalogue/PUB16803

- Scotland: Published on the Information Services Division (ISD) Scotland website at: www.isdscotland.org/Health-Topics/Cancer/Breast-Screening
- Northern Ireland: Published on the Northern Ireland Cancer Screening Programmes website at: www.cancerscreening.hscni.net/2051.htm

Cervical screening statistics for:

- England: published on the Health and Social Care Information Centre website at: www.hscic.gov.uk/catalogue/PUB11889
- Scotland: published on the Information Services Division (ISD) Scotland website at: www.isdscotland.org/Health-Topics/Cancer/Cervical-Screening
- Wales: published on the Screening Services Wales website at: www.screeningservices.org.uk/csw/prof/reports
- Northern Ireland: published on the Northern Ireland Cancer Screening Programmes website at: www.cancerscreening.hscni.net/pdf/ANNUAL_REPORT_2010-11.pdf

Bowel screening statistics for:

- England: R Logan et al. in 2011 examined the ‘Outcomes of the Bowel Cancer Screening Programme (BCSP) in England after the first one million tests’. GUT. 2011 December. Published online at: http://gut.bmj.com/content/early/2011/11/22/gutjnl-2011-300843.full
- Palmer et al. in 2014 published a study examining factors affecting uptake in the BCSP: www.nature.com/bjc/journal/vaop/ncurrent/full/bjc2014125a.html
- results for the flexible-sigmoidoscopy trail can be found at: www.cancerscreening.nhs.uk/bowel/uk-flexible-sigmoidoscopy-screening-trial-slides.pdf
- Scotland: ‘Scottish Bowel Screening Programme - Key Performance Indicators Report: May 2012 data submission, Invitations between 1 November 2009 and 31 October 2011’ published on the ISD Scotland website at: www.isdscotland.org/Health-Topics/Cancer/Bowel-Screening
Routes to diagnosis

What is it?

‘Routes to diagnosis’ defines a methodology by which the route the patient follows to the point of diagnosis can be categorised, in order to examine demographic, organisational, service and personal reasons for delayed diagnosis. Administrative hospital episode statistics (HES) data are combined with cancer waiting times (CWT) data, data from the cancer screening programmes and cancer registration data from the National Cancer Data Repository (NCDR). Using these datasets every case of cancer registered is categorised into one of eight ‘routes to diagnosis’.

Different cancers show substantial differences in the proportion of cases that present by each route, in reasonable agreement with previous clinical studies. Patients presenting via emergency routes have substantially lower one-year relative survival. This methodology can be used to explore possible reasons for delayed diagnosis, direct the focus of early diagnosis initiatives and identify areas for further research.


What is the latest data available?

- for England: patients diagnosed from 2006 to 2010

Useful data sources:

- a range of information detailed below is provided on the NCIN website: www.ncin.org.uk/publications/routes_to_diagnosis.aspx
- workbooks for routes to diagnosis 2006 to 2010 cohort data. These show the percentage of total cancers that are diagnosed by each route by site, sex, age, deprivation quintile and ethnicity, and the relative survival for 1, 3, 6, 9, 12, 24 and 36 month intervals for each route. These new workbooks include a number of extra cancer sites and data at strategic clinical network (SCN) level and CCG level. They can be found at: www.ncin.org.uk/view?rid=2645 and here: www.ncin.org.uk/view?rid=2644. Updates are planned for the end of 2015 to over patients diagnosed in 2013
- a report on major resections by route: www.ncin.org.uk/view?rid=2972
- routes to diagnosis 2006 to 2008 NCIN information supplement: the report summarises the routes by cancer type, age group and deprivation quintile
Associated relative survival estimates are shown for 1, 3, 6, 9 and 12 month survival intervals with 12 month survival also broken down by age group

- routes to diagnosis 2006-2008 Workbook: Shows the percentage of total cancers that are diagnosed by each route, and the relative survival for each route
- routes to diagnosis 2006 to 2010 technical document: summarises the data sources and methodology used for this routes to diagnosis project
- the NCIN data briefing ‘Routes to diagnosis for cancer of unknown primary’. See: www.ncin.org.uk/view?rid=2597
- Routes to Diagnosis data are available from the CCT, which is a web-based database of multiple data sources and also includes incidence, mortality and survival data for commissioners and providers. There are two levels of access – public open access (to comply with the government open data policy) and professional NHS (login required to meet information governance requirements). See: www.ncin.org.uk/cancer_information_tools/cct or www.cancertoolkit.co.uk
Improving outcomes for cancer patients: quality of life and patient experience

Cancer prevalence

What is it?

Cancer prevalence is the number of people, or the proportion of the population, who are alive on a specified date and have previously been diagnosed with cancer. As such it is an indicator of the burden of cancer and can help to inform health care service planning. The number of people alive with a diagnosis of cancer is increasing as incidence rises and survival improves.

What is the latest data available?

- UK estimates for 2010
- European estimates for 2012

Useful data sources:

- the Macmillan-NCIN partnership has produced an interactive Excel spreadsheet for 20-year cancer prevalence based on people diagnosed with cancer in the period 1991 to 2010 and alive at the end of December 2010, for all malignant cancers combined (excluding non-melanoma skin cancer). The spreadsheet provides cancer prevalence data by time since diagnosis, age at diagnosis, age at end of 2010, sex, UK constituent countries, Strategic Clinical Network for England, and deprivation quintile for England: www.ncin.org.uk/view?rid=2493. This prevalence data will be provided by other geographies in the future
- this data is available from the CCT. There are two levels of access – public open access (to comply with the government open data policy) and professional NHS (login required to meet information governance requirements). See: www.ncin.org.uk/cancer_information_tools/cct or www.cancertoolkit.co.uk
- Cancer Prevalence e-Atlas available on the NCIN website at: www.ncin.org.uk/Prevalence/1_5_10_Year/atlas.html.
International comparisons:

- one, three and five-year cancer prevalence estimates for 40 European countries for 2012 are available on the EUCAN website at: http://eco.iarc.fr/EUCAN/Default.aspx

Prevalence projections:

- ‘The number of older people (aged 65 and over) living with cancer in the UK was set to more than treble by 2040, ie from 1.3 million in 2010 to 4.1 million by 2040’ is a statistic quoted from a paper published by J Maddams et al. in 2012 ‘Projections of cancer prevalence in the United Kingdom, 2010–2040’. British Journal of Cancer 2012; 107:1195 to 1202. See: www.nature.com/bjc/journal/v107/n7/abs/bjc2012366a.html
Patient experience

What is it?

The National Cancer Patient Experience Survey is undertaken by the Department of Health and provides an insight into the level of care experienced by cancer patients across England who were treated as day cases or inpatients. NHS trusts providing cancer services identify cancer patients of which a proportion chose to take part. Each of the NHS trusts taking part in the survey is provided with a bespoke report which enables them to compare their provision of cancer patient experience with other trusts, and to drive quality improvements and better outcomes locally.

What is the latest data available?

- for England: Cancer Patient Experience Survey 2014

Useful data sources:

- for Northern Ireland: results of a 2013 survey are expected later in the year: www.quality-health.co.uk/surveys/northern-ireland-cancer-patient-experience-survey
Quality of life

What is it?

The Patient Reported Outcome Measures (PROMs) pilot survey was carried out by the Department of Health to demonstrate the feasibility of collecting information on the quality of life of cancer survivors. The survey was conducted to understand the quality of life health outcomes of a sample of adult cancer patients at various time points since diagnosis. This is the largest survey of cancer survivors covering multiple cancer types, ever conducted in Europe.

The quality of life for survivors of breast, colorectal, prostate cancer and non-Hodgkin’s lymphoma (NHL) at one, two, three and five years after diagnosis, were assessed using a standard health questionnaire (EQ-5D). This questionnaire has five items covering problems with walking about, washing or dressing, doing usual activities, pain or discomfort and anxiety or depression. Tumour-specific questions were drawn from the relevant Functional Assessment of Cancer Therapy (FACT) questionnaires.

A total of 43 questions were common to all tumour groups, with around 20 to 30 additional questions depending on tumour type. Future PROMs surveys will include additional cancer sites.

What is the latest data available?

- Pilot Patient Reported Outcome Measures Survey conducted in July 2011
- patients resident in the areas covered by the three former cancer registries of Eastern Cancer Registration and Information Centre (ECRIC), Thames Cancer Registry (TCR) and West Midlands Cancer Intelligence Unit (WMCIU)
- nearly 3,300 cancer patients participated in the survey, a response rate of 66%

Useful data sources:

- a paper assessing the feasibility of collecting PROMS, published in 2013: bmjopen.bmj.com/content/3/4/e002317.short
Quality of care

What is it?

The National Peer Review Programme (NPRP) is a national quality assurance programme for NHS cancer services. A first round of peer review commenced at a regional level in 2001 and the national programme was established in 2004. The programme involves both self-assessment by multidisciplinary teams (MDTs) and external reviews of MDTs conducted by professional peers, against nationally agreed ‘quality measures’. The NPRP aims to improve the care of people with cancer and their families.

Following a national consultation in 2008, the number of measures were reduced by approximately 40% and greater emphasis placed on outputs and outcomes with the introduction of clinical lines of enquiry (CLE). The use of CLE has now been extended to six tumour types; breast, lung, colorectal, upper gastrointestinal, gynaecology, and head and neck services. This has been received well by clinical teams and has moved the focus of peer review towards clinical outcomes.

What is the latest data available?

- the NPRP Report 2012 to 2013 (An overview of the findings from the 2012 to 2013 NPRP of Cancer Services in England) was published in October 2013
- individual reports for the 27 area teams for the 2012 to 2013 cycle of the NPRP

Useful data sources:

- the National and Cancer Network level reports can be found on the resource section of the Cancer Quality Information Network System (CQuINS) website at: www.cquins.nhs.uk/?menu=resources
- CLE briefing papers and peer review reports can be found on the public and NHS view of the CCT at: www.ncin.org.uk/cancer_information_tools/cct or www.cancertoolkit.co.uk
Improving outcomes for cancer patients: better treatment

Treatment and quality of care

What is it?

The quality of treatment available to cancer patients is also an important determinant of outcomes. Information about the treatments available and the outcomes of care delivered is necessary for patients to make informed choices, for commissioners to effectively performance manage services and for healthcare professionals to identify the need for, and to introduce, improvements. There is a wide range of data and research available about cancer treatment and hospital activity.

In England most national statistics are based on the HES, the national statistical data warehouse for England recording data on the care provided by NHS hospitals and for NHS hospital patients treated elsewhere. HES is the data source for a wide range of healthcare analysis by the NHS, government and many other organisations and individuals. In 2008, a National Cancer Data Repository was set up. This links a range of patient data related to cancer, including cancer registry records and HES. This source of linked data is invaluable for improving our understanding of cancer and the patient journey. In 2012 this system was incorporated in to the Cancer Analysis System to analyse data from the NCRS. Examples of analysis given below include cancer patients receiving major surgical resections and 30-day postoperative mortality after colorectal cancer surgery.

What is the latest data available?

- varies by source

Useful data sources:

- tabulations of HES data relating to admitted patient care in NHS hospitals in England, for a range of topics, including operations and diagnoses are available on Health and Social Care Information Centre website at: www.hscic.gov.uk/hes
- provisional monthly HES data for England (admitted patient care, outpatients, accident and emergency data from April 2014 to February 2015) are available on the Health and Social Care Information Centre website at: www.hscic.gov.uk/catalogue/PUB17615
the National Clinical Analysis and Specialised Applications Team (NATCANSAT) website hosts a number of national and academic publications: www.canceruk.net/rt/rtds.aspx
radiotherapy profiles provide information about key indicators relating to radiotherapy services in England. These are available from the NCIN CCT, for which login access is needed: www.ncin.org.uk/cancer_information_tools/cct or www.cancertoolkit.co.uk
radiotherapy data and charts are also available via the CCT
national collection of all cancer chemotherapy in the NHS in England commenced in April 2012, for more information see: The Systemic Anti-Cancer Therapy (SACT) chemotherapy dataset website at: www.chemodataset.nhs.uk/home
Cancer Outcomes and Services Dataset (COSD) replaced the previous National Cancer Dataset as the new national standard for reporting cancer in the NHS in England as of January 2013. For more information see: www.ncin.org.uk/collecting_and_using_data/data_collection/cosd.aspx
imaging is a central tool in detecting and diagnosing cancer. The Diagnostic Imaging Dataset (DID) is a central collection of detailed information about diagnostic imaging tests, such as ultrasound and MRI carried out on NHS patients: www.england.nhs.uk/statistics/statistical-work-areas/diagnostic-imaging-dataset Imaging is used in the diagnosis of cancer, with commentary on early diagnosis and imaging relating to cancer here: www.england.nhs.uk/statistics/wp-content/uploads/sites/2/2014/06/Technical-Report-2013-14-DID-pdf-842-KB.pdf
the following are published in the Improving Cancer Outcomes Strategy: information supplement available on the NCIN website at: www.ncin.org.uk/view.aspx?rid=663
major urological operations: for England (table 4) and by hospital trust (appendix 5); major oesophago-gastric operations: England (table 5) and by hospital trust (appendix 5), percentage of laparoscopic colorectal resections, England (table 6); average length of ordinary episode (days) (table 8)
GP profiles for cancer provide information about key indicators relating to cancer services for most GP practices in England. These are available via the CCT (both public and professional view) www.cancertoolkit.co.uk. Some information has been removed to protect patient confidentiality. Unsuppressed versions of the profiles remain available to NHS users and GPs
CCG profiles for Cancer will provide information about 26 key indicators relating to cancer services for every CCG in England. They are intended to help CCGs think about clinical practice and service delivery in cancer. These are available through the NCIN website at:

www.ncin.org.uk/cancer_information_tools/profiles/pctprofiles.aspx, on both the public and professional view of the CCT at:
www.ncin.org.uk/cancer_information_tools/cct or www.cancertoolkit.co.uk

- service profiles for cancer provide information about key indicators relating to cancer services for breast, colorectal, lung, gynaecological, head and neck, oesophago-gastric cancer and sarcoma by NHS trust in England. These can be accessed via the CCT, NHS professional view (access required):
  www.ncin.org.uk/cancer_information_tools/cct or www.cancertoolkit.co.uk. As part of the government transparency open data policy - lung profiles are available in the CCT public view following governance approval to share data publically
- cancer nurse specialist reports are available on the public and professional view of the CCT at: www.ncin.org.uk/cancer_information_tools/cct or www.cancertoolkit.co.uk
- chemotherapy nursing workforce reports are available on the public and professional view of the CCT at: www.ncin.org.uk/cancer_information_tools/cct or www.cancertoolkit.co.uk
- CWT data is available from the CCT, professional view for which login access is needed: www.ncin.org.uk/cancer_information_tools/cct or www.cancertoolkit.co.uk
- the following NCIN data briefings are available on the NCIN website at:
  www.ncin.org.uk/publications/data_briefings/default.aspx
  - high procedure volume is associated with improved survival after lung cancer surgery
  - urgent GP referral rates for suspected cancer
  - NHS treated cancer patients receiving major surgical resections
  - time from final surgery to radiotherapy for screen-detected breast cancer
  - thirty-day postoperative mortality after colorectal cancer surgery in England
  - characteristics of individuals with colorectal cancer who die rapidly after their diagnosis
  - recurrent and metastatic breast cancer
- peer-reviewed publications making use of the NCDR are listed on the NCIN website at: www.ncin.org.uk/publications/peer_reviewed.aspx
- NHS comparators is an analytical service for commissioners and providers for which login access is needed: www.hscic.gov.uk/nhscomparators
- national radiotherapy dataset (RTDS) microsite is an online analytical tools providing data for commissioners and providers for which login access is needed: www.rtds.nhs.uk/microsite/rtds/
Treatment outcomes data

What is it?

Patients, commissioners and healthcare professionals all have an interest in understanding variations in the quality of treatment and the outcomes achieved. Clinical audit provides a valuable mechanism for assessing variations in treatment. There are currently five nationally designated clinical audits relating to different cancers.

The intention is that all acute NHS trusts that provide any type of service for relevant groups of cancer patients should participate in these audits, collecting and reporting a complete dataset on each of their patients. This will allow valid comparisons to be made between trusts, taking account of case-mix variations (e.g. stage of disease, age and co-morbidity). These comparisons should in turn help to drive up quality.

What is the latest data available?

- the National Bowel Cancer Audit (NBCA) Report 2014 – audit period April 2012 to March 2013
- the National Head and Neck Cancer Audit (DAHNO) Report 2013 – audit period November 2012 to October 2013
- the National Lung Cancer Data Audit (LUCADA) Report 2014 – audit period 2013
- the National Oesophago-gastric Cancer Audit (NOGCA) Report 2014 – audit period April 2011 to March 2013

Useful data sources:

- audit reports are published on the Health and Social Care Information Centre website at: www.hscic.gov.uk/Article/1806
Improving outcomes for cancer patients: reducing inequalities

What is it?

Reducing cancer inequality is of critical importance. Considerable inequalities in cancer incidence and outcomes still exist between different groups in the UK. Accurate information on the extent, nature and causes of cancer inequalities is important, if these are to be reduced in future.

What is the latest data available?

- whenever possible NCIN analyses consider the different equalities domains, meaning that a wide range of publications are relevant to this topic
- an overview of key equality metrics including age, sex, deprivation and ethnicity covering the most recent data available is available on the NCIN website

Useful data sources:

- the 2015 NCIN report on equality metrics can be found at: www.ncin.org.uk/view?rid=2991
- a report at UK level examining deprivation is available from the NCIN website: www.ncin.org.uk/view?rid=2691
- a report focusing on variation by age, especially older people available at: www.ncin.org.uk/view?rid=2950
- evidence to March 2010 on cancer inequalities in England – NCIN report. This report was originally published as an annex to the National Cancer Equalities Initiative (NCEI) report ‘Reducing cancer inequality: evidence, progress and making it happen’. The NCIN report is available on the NCIN website at: www.ncin.org.uk/view.aspx?rid=169
- the NCIN publishes reports on the NCIN website at: www.ncin.org.uk/publications/reports. Examples include:
  - Older people and cancer
  - Deprivation and blood cancer survival in England: analysis of cancer registration data 2000 to 2007
  - Estimated completeness of ascertainment for childhood cancer in the UK, 2005 to 2010
  - Frequency of non-specific morphology codes (ICD-O M) within the NCDR (2007 to 2009) for cancer in Teenagers and Young Adults (TYA)
  - Routes to diagnosis: investigating the different pathways for cancer referrals in
England for TYA

- the following NCIN data briefings are published on the NCIN website at: www.ncin.org.uk/publications/data_briefings/default.aspx. Examples include:
  - Interpreting geographic variation in cancer stage
  - Penile Cancer – Incidence by Age
  - Vulval Cancer – Trends and Variations by Age
  - Short-term survival of children with cancer

- a report looking at variation in incidence and mortality between males and females for the Republic of Ireland can be found here: www.ncri.ie/publications/research-reports/report-excess-burden-cancer-among-men-republic-ireland

- awareness measure tool (see section on cancer awareness above) provides a range of statistics by socio-economic group


- an article examining the cancer patient experience survey (see previous section) by sex, age and ethnicity: bmjopen.bmj.com/content/4/2/e004567.full.pdf+html

- geographic inequalities are accessible via the public health outcomes framework for measure on early staged cancers and screening: www.phoutcomes.info (under health improvement starting at indicator 2.19)
## Glossary of terms

<table>
<thead>
<tr>
<th>Abbreviation</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>ABS</td>
<td>Association of Breast Surgery</td>
</tr>
<tr>
<td>ASR</td>
<td>age-standardised rate</td>
</tr>
<tr>
<td>BCSP</td>
<td>Bowel Cancer Screening Programme</td>
</tr>
<tr>
<td>CAM</td>
<td>Cancer Awareness Measure</td>
</tr>
<tr>
<td>CCG</td>
<td>clinical commissioning group</td>
</tr>
<tr>
<td>CCT</td>
<td>Cancer Commissioning Toolkit</td>
</tr>
<tr>
<td>CIN</td>
<td>Section of Cancer Information</td>
</tr>
<tr>
<td>CLE</td>
<td>clinical lines of enquiry</td>
</tr>
<tr>
<td>COSD</td>
<td>Cancer Outcomes and Services Dataset</td>
</tr>
<tr>
<td>CQuINS</td>
<td>Cancer Quality Information Network System</td>
</tr>
<tr>
<td>CRUK</td>
<td>Cancer Research UK</td>
</tr>
<tr>
<td>CWT</td>
<td>Cancer Waiting Times</td>
</tr>
<tr>
<td>DAHNO</td>
<td>The National Head and Neck Cancer Audit</td>
</tr>
<tr>
<td>DID</td>
<td>Diagnostic Imaging Dataset</td>
</tr>
<tr>
<td>ECO</td>
<td>European Cancer Observatory</td>
</tr>
<tr>
<td>ECRIC</td>
<td>Eastern Cancer Registration and Information Centre</td>
</tr>
<tr>
<td>EUROCARE</td>
<td>EUROpean CAncer REgistry</td>
</tr>
<tr>
<td>FACT</td>
<td>Functional Assessment of Cancer Therapy</td>
</tr>
<tr>
<td>HES</td>
<td>Hospital Episode Statistics</td>
</tr>
<tr>
<td>IARC</td>
<td>International Agency for Research on Cancer</td>
</tr>
<tr>
<td>ISD</td>
<td>Information Services Division</td>
</tr>
<tr>
<td>LSHTM</td>
<td>London of School of Hygiene and Tropical Medicine</td>
</tr>
<tr>
<td>LUCADA</td>
<td>The National Lung Cancer Data Audit</td>
</tr>
<tr>
<td>MDT</td>
<td>multidisciplinary team</td>
</tr>
<tr>
<td>MRI</td>
<td>magnetic resonance imaging</td>
</tr>
<tr>
<td>NAEDI</td>
<td>National Awareness and Early Diagnosis Initiative</td>
</tr>
<tr>
<td>NATCANSAT</td>
<td>National Clinical Analysis and Specialised Applications Team</td>
</tr>
<tr>
<td>NBCA</td>
<td>National Bowel Cancer Audit</td>
</tr>
<tr>
<td>NCDR</td>
<td>National Cancer Data Repository</td>
</tr>
<tr>
<td>NCEI</td>
<td>National Cancer Equalities Initiative</td>
</tr>
<tr>
<td>NCIN</td>
<td>National Cancer Intelligence Network</td>
</tr>
<tr>
<td>NCRS</td>
<td>National Cancer Registration Service</td>
</tr>
<tr>
<td>NCVIN</td>
<td>National Cardiovascular Intelligence Network</td>
</tr>
<tr>
<td>NEoLCIN</td>
<td>National End of Life Care Intelligence Network</td>
</tr>
<tr>
<td>NHL</td>
<td>non-Hodgkin’s lymphoma</td>
</tr>
<tr>
<td>NMHIN</td>
<td>National Mental Health Intelligence Network</td>
</tr>
<tr>
<td>NOGCA</td>
<td>The National Oesophago-gastric Cancer Audit</td>
</tr>
<tr>
<td>NPRP</td>
<td>National Peer Review Programme</td>
</tr>
<tr>
<td>ONS</td>
<td>Office for National Statistics</td>
</tr>
<tr>
<td>PCT</td>
<td>primary care trust</td>
</tr>
<tr>
<td>PROMs</td>
<td>Patient Reported Outcome Measures</td>
</tr>
<tr>
<td>RTDS</td>
<td>national radiotherapy dataset</td>
</tr>
<tr>
<td>SACT</td>
<td>Systemic Anti-Cancer Therapy</td>
</tr>
<tr>
<td>SCN</td>
<td>strategic clinical network</td>
</tr>
<tr>
<td>TCR</td>
<td>Thames Cancer Registry</td>
</tr>
<tr>
<td>Abbreviation</td>
<td>Description</td>
</tr>
<tr>
<td>--------------</td>
<td>-------------</td>
</tr>
<tr>
<td>TYA</td>
<td>teenagers and young adults</td>
</tr>
<tr>
<td>UKCIS</td>
<td>UK Cancer Information System</td>
</tr>
<tr>
<td>UKIACR</td>
<td>UK and Ireland Association of Cancer Registries</td>
</tr>
<tr>
<td>WMCIU</td>
<td>West Midlands Cancer Intelligence Unit</td>
</tr>
</tbody>
</table>